ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
The evolution of lung cancer treatment
Monday, July 29, 2013
Submitted by
Source
Source Name: The Lancet
Cancer Research UK announced a large investment into TRACERx, a project aimed at identifying genetic abnormalities in lung cancers and following their evolution over the lifetime of the patient. Similar efforts are underway in France and the US.
Printer-friendly
